Aeterna Zentaris (AEZS +16%) and Keryx Biopharmaceuticals (KERX +18.6%) shares soar on a bullish...

|By:, SA News Editor

Aeterna Zentaris (AEZS +16%) and Keryx Biopharmaceuticals (KERX +18.6%) shares soar on a bullish analysis by Jeremy Richards in SA. Phase 3 clinical information is expected within two weeks on their top pipeline drug Perifosine; Richards believes the data is positive and the market has not realized the potential for the two companies.